ACRS logo

ACRS Aclaris Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$5.78
-0.08 (-1.37%)

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet…

Market Cap: $807.26Mwww.aclaristx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

130
130
Aug 10Aug 10

Quote

Day Range
$5.64 – $5.88
52-Week Range
$1.74 – $6.51
Volume
$644.4K
Market Cap
$807.26M
50-Day Avg
$5.25
200-Day Avg
$3.93
Prev Close
$5.86
Open
$5.88

Valuation & Ratios

P/E Ratio
-5.68
EPS
$-0.53
P/B Ratio
3.58
P/S Ratio
47.18
Debt/Equity
0.02
Current Ratio
5.28
Dividend Yield
+0.0%
Gross Margin
+73.3%

Returns & Efficiency

Return on Equity
-63.0%
Return on Assets
-40.5%
FCF Yield
-12.8%
EV/EBITDA
-5.45

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$7.83M$-64.92M$-0.53
2024$18.72M$-132.06M$-1.71
2023$31.25M$-88.48M$-1.27
2022$29.75M$-86.91M$-1.33
2021$6.76M$-90.86M$-1.60

Social Signal Score

80
5d
30d
80
1 mentions
60d
80
1 mentions
90d
80
1 mentions
news: 1

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-0.17 per share

5of 7 quarters beat consensus

Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.15 vs $-0.16beat
  • Thu, May 7$-0.15 vs $-0.16beat
  • Thu, Feb 26$-0.16 vs $-0.15miss
  • Thu, Nov 6$-0.12 vs $-0.13beat
  • Thu, Aug 7$-0.13 vs $-0.13beat
  • Thu, May 8$-0.12 vs $-0.17beat

Estimates and results for ACRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ACRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newszacks.com·5d ago·Positive

    Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    View source ↗